Oral Milrinone in Severe Chronic Heart Failure

S. Desjardins, M. Packer, G. D. Curfman

Research output: Contribution to journalLetterpeer-review

4 Scopus citations


To the Editor: Packer et al. (Nov. 21 issue)1 reported that the unfavorable effect of milrinone on the survival of patients with severe congestive heart failure contrasted with the results of previous studies in laboratory animals. The authors suggested that in rats, milrinone does not inhibit phosphodiesterase, increase levels of cyclic AMP (cAMP), or exert positive inotropic effects but, rather, acts as a vasodilator. However, Weishaar et al.,2 cited by Packer et al., did not test milrinone in their study. Although it is well accepted that milrinone is not a positive inotropic agent in rats, the drug has been shown…

Original languageEnglish (US)
Pages (from-to)1565-1567
Number of pages3
JournalNew England Journal of Medicine
Issue number23
StatePublished - Jun 4 1992

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Oral Milrinone in Severe Chronic Heart Failure'. Together they form a unique fingerprint.

Cite this